Table 2.
Cross-sectional association of asthma outcomes on serum adiponectin concentrations; CARDIA year 15 examination.
| Outcome | Women with asthma (n = 258) | Men with asthma (n = 153) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted for block covariates and BMI | N value | Unadjusted | Adjusted for block covariates and BMI | N value | |||||
| OR or rate ratio (95% CI) | p Value | OR or rate ratio (95% CI) | p Value | OR or rate ratio (95% CI) | p Value | OR or rate ratio (95% CI) | p Value | |||
| Active disease | 0.51 (0.31, 0.82) | 0.006 | 0.84 (0.50, 1.42) | 0.52 | 171/258 | 2.76 (1.31, 5.85) | 0.008 | 2.15 (1.10, 4.23) | 0.03 | 77/153 |
| Use of any asthma medication | 0.96 (0.64, 1.44) | 0.83 | 1.35 (0.83, 2.21) | 0.23 | 108/258 | 2.30 (1.23, 4.30) | 0.009 | 2.41 (1.19, 4.90) | 0.01 | 56/153 |
| Number of respiratory symptoms | 0.90 (0.81, 1.00) | 0.06 | 1.07 (0.94, 1.21) | 0.33 | 258 | 1.35 (1.15, 1.59) | <0.001 | 1.33 (1.11, 1.61) | 0.002 | 153 |
| Number of asthma medications | 0.99 (0.77, 1.26) | 0.92 | 1.15 (0.90, 1.47) | 0.37 | 258 | 2.06 (1.45, 2.95) | <0.001 | 2.00 (1.34, 3.01) | <0.001 | 153 |
All variables were measured at CARDIA year 15 examination. Natural logarithmic values of serum adiponectin concentration are presented; the estimates are per unit of log-transformed adiponectin; the entire range of log-transformed adiponectin was 3.0. Slope parameters for number of respiratory symptoms and for number of asthma medications used, was obtained from Poisson regression – estimates for men with asthma were 0.30 ± 0.08 and 0.29 ± 0.09 without and with adjustment respectively for number of respiratory symptoms and 0.73 ± 0.18 and 0.70 ± 0.21 without and with adjustment respectively for number of asthma medications used. For women with asthma, these estimates were not significant. Rate ratios corresponding to the slope parameters are provided in the table. Interactions – additionally, significant interactions were noted between sex and adiponectin on the presence of active disease (p = 0.003); use of any asthma medication (p = 0.04); number of respiratory symptoms (p < 0.001); and number of asthma medications used (p = 0.002), after adjusting for BMI and block covariates. BMI, body mass index; CARDIA, coronary artery risk development in young adults; OR, odds ratio; CI, confidence intervals.